Introduction
Modern medicine has transformed outcomes for many serious conditions. In cardiology, oncology, and critical care, it is often necessary to use multiple medications in combination to stabilise disease and improve survival. In this sense, polypharmacy is not inherently problematic. It is often appropriate and, in many cases, life-saving.
However, when multiple medications are used together—particularly those that act on the brain—the effects are not simply additive. Instead, there is a complex interaction between drugs and brain systems. In some cases, these interactions alter cognition, emotion, and behaviour in ways that are not always recognised.
In clinical practice, this is seen most clearly in patients who present as slowed, emotionally blunted, disengaged, or cognitively dulled. The key question is not simply what condition the patient has, but how much of what we are observing clinically reflects the condition—and how much reflects the treatment.
What Is Polypharmacy?
Polypharmacy is commonly defined as the use of five or more medications. This threshold is widely used in research as a point at which the risk of adverse effects, drug interactions, and functional decline begins to increase.
However, the number itself is not the whole story. A patient taking several well-targeted cardiovascular medications may benefit substantially from treatment. In contrast, a patient taking multiple centrally (brain) acting medications may experience significant effects on brain function, even at lower numbers.
For this reason, clinicians increasingly distinguish between:
- Appropriate polypharmacy: where each medication has a clear, evidence-based role
- Problematic polypharmacy: where medications accumulate without clear ongoing benefit, or where their combined effects impair function.
Why Psychotropic Polypharmacy Is Different
Psychotropic medications—including antidepressants, antipsychotics, mood stabilisers, benzodiazepines, and sedative agents—act directly on brain systems involved in:
- Arousal and alertness
- Emotional regulation
- Motivation and reward
- Cognitive processing
- Motor control
When these medications are combined, their effects can interact in complex ways. The literature suggests that while combination treatment is sometimes necessary, the evidence for additive benefit is often limited outside specific indications. At the same time, there is consistent evidence that increasing psychotropic load is associated with:
- Sedation and fatigue
- Cognitive slowing and impaired attention
- Emotional blunting
- Reduced motivation and initiative
- Increased risk of falls and functional decline
- Movement disorders, including extrapyramidal side effects and tardive dyskinesia
These effects are not always dramatic, but they can significantly alter how a person functions in daily life and during rehabilitation.
When Medication Effects Mimic Illness
One of the central clinical challenges is that medication effects can resemble the very conditions they are intended to treat.
For example:
- Apathy and reduced initiative may be interpreted as depression, but may reflect dopamine blockade
- Slowed thinking and reduced expression may resemble brain injury or negative symptoms, but may reflect medication effects
- Agitation may be interpreted as anxiety or mood instability, but may in some cases represent akathisia (drug-induced restlessness and an inability to remain still)
This overlap makes it difficult to distinguish illness from treatment effects without careful review.
The Transition from Acute Care to Rehabilitation
A particularly important and under-recognised issue arises during transitions in care.
In acute medical or intensive care settings, medications are often used appropriately to stabilise patients. Sedatives and antipsychotics may be required to manage agitation, delirium, or ICU-related confusional states associated with ventilation and critical illness. However, as patients stabilise and move into rehabilitation, the goals of care change.
Rehabilitation requires engagement, emotional responsiveness, attention and learning, and motivation and participation. Yet in clinical practice, it is not uncommon for patients to arrive in rehabilitation on medication regimens that were initiated during acute care and have not been fully reviewed. The result can be a patient who is sedated, emotionally blunted, cognitively slowed and, worst of all, disengaged from rehabilitative therapy.
In this context, treatment that was appropriate in one phase of care may become counterproductive in another.
When patients are transferred from acute care to a rehabilitation setting, their medication should be actively reviewed rather than simply continued unchanged. By definition, if a patient is ready for rehabilitation, their clinical state has evolved—and their treatment should evolve accordingly.
The Brain Needs to Be Able to Respond
Effective rehabilitation depends on neuroplasticity—the brain’s ability to adapt, learn, and reorganise.
For this to occur, the brain must be sufficiently alert, emotionally responsive, able to process, comprehend and integrate information, and capable of generating motivation and action. Excessive psychotropic burden can markedly reduce these capacities.
This does not mean that medication should be avoided. Rather, it highlights an important principle:
Medication should support brain function, not suppress it.
Functional Outcomes Matter
In many treatment settings, success is defined in terms of symptom reduction. However, from a neuropsychological perspective, a broader set of questions is equally important:
- Is the patient thinking clearly?
- Are they emotionally engaged?
- Are they able to initiate and sustain activity?
- Are they participating meaningfully in their own recovery?
If these capacities are compromised, it is important to consider whether medication effects may be contributing.
The Importance of Regular Review
Polypharmacy often develops gradually over time. Medications are added in response to new symptoms, side effects, or changing circumstances. What is less common is systematic review and simplification.
Best practice should involve regular reassessment of each medication’s role and consideration of cumulative effects. It is also important to identify medications that may no longer be necessary. A critical element of care should entail adjustment of dosing to minimise cognitive and emotional side effects.
This process is sometimes referred to as “deprescribing,” and there is increasing awareness related to its clinical importance. However, the goal is not simply reduction. Rather, the goal is optimisation.
A Collaborative Approach
Decisions about medication should always be made collaboratively between patients and their treating doctors. Medication can be essential, and in many cases it plays a critical role in stabilisation and recovery.
At the same time, patients are entitled to understand:
- The potential effects of individual medications
- The possible cumulative effects of combinations
- How these may influence cognition, emotion, and function
It is also important to recognise that, in acute care settings such as ICU, patients may not be in a position to provide informed consent at the time treatment is initiated. As clinical status improves, there should be a renewed opportunity for informed discussion and review.
Such discussion allows for more precise, transparent, and individualised care.
A Neuropsychological Perspective
At Ormond Neuroscience, the focus is on how the brain is functioning as a system. As we often say:
We don’t force the brain to heal.
We create the right conditions—
biological, emotional, cognitive, and social
—and the brain does what complex systems do:
—it self-organises.
Treatment approaches such as Neuroharmonics and vagus nerve stimulation are designed to support:
- Regulation
- Responsiveness
- Adaptation
- Emotional equanimity
- Cognitive prowess
For these approaches to be effective, the brain needs to be able to engage with the process of change.
In some cases, this requires careful consideration of medication regimens to ensure that cognitive and emotional responsiveness are preserved. Patients who are emotionally blunted by medication may have reduced capacity to appreciate the relevance of rehabilitation, which can limit engagement and progress.
Conclusion
Polypharmacy is not inherently harmful. In many areas of medicine, it is necessary and beneficial. However, when multiple medications—particularly psychotropic agents—are combined, their effects on brain function can become significant.
The key issue is not simply how many medications are being used, but how they are affecting the person as a whole—especially their capacity to engage meaningfully with life and treatment.
As patients move from acute care into recovery and rehabilitation, treatment should be recalibrated to support engagement, cognition, and adaptation. In this context, the goal is not less treatment, but better treatment—treatment that enables the brain to function, respond, and recover.
Treatment that facilitates the brain’s capacity for self-organisation.
References
American Geriatrics Society. 2023 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12478568/
Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a longstanding clinical practice. CNS Drugs.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8318953/
Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. Journal of the American Medical Directors Association.
https://doi.org/10.1016/j.jamda.2019.10.022
Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology.
https://pubmed.ncbi.nlm.nih.gov/22742913/
Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. European Geriatric Medicine.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8149355/
World Health Organization. Medication Safety in Polypharmacy.
https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-11-eng.pdf
FAQ (for SEO / Schema)
What is polypharmacy?
Polypharmacy refers to the use of multiple medications, commonly defined as five or more concurrent prescription drugs. It is associated with increased risk of interactions and side effects, particularly in older adults.
Is polypharmacy always harmful?
No. In many medical conditions, such as cardiovascular disease, multiple medications are necessary and beneficial. The key issue is whether each medication remains appropriate and how the combination affects overall function.
What is psychotropic polypharmacy?
Psychotropic polypharmacy refers to the use of multiple medications that affect brain function, such as antidepressants, antipsychotics, and sedatives. These combinations can influence cognition, emotion, and behaviour.
Can medication affect thinking and motivation?
Yes. Some medications, particularly when combined, can lead to sedation, cognitive slowing, and reduced motivation. These effects can sometimes be mistaken for symptoms of illness.
Should patients stop their medication?
No. Medication changes should always be discussed with a qualified healthcare professional. The goal is not to stop treatment, but to ensure that it is optimised and appropriate.
